ProCE Banner Activity

How I Manage Patients With Chemotherapy-Refractory Metastatic CRC

Clinical Thought
As patients progress through first-line and second-line therapy, selection of therapy becomes more complicated and nuanced. Here’s how I navigate the multiple treatment options.

Released: September 11, 2017

Expiration: September 10, 2018

No longer available for credit.

Share

Faculty

John Strickler

John Strickler, MD

Assistant Professor
Division of Medical Oncology
Department of Medicine
Duke University
Durham, North Carolina

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Bayer Healthcare Pharma

Genentech TEXT Only

Lilly

Taiho Pharmaceuticals

Faculty Disclosure

Primary Author

John Strickler, MD

Assistant Professor
Division of Medical Oncology
Department of Medicine
Duke University
Durham, North Carolina

John Strickler, MD, has disclosed that he has received consulting fees from Amgen, Celgene, and Genentech/Roche and he has received funds for research support from OncoMed.